- Home
- LXEH vs RDHL Comparison
LXEH vs RDHL Comparison
Compare LXEH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | RDHL |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.3M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LXEH | RDHL |
|---|---|---|
| Price | $1.46 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 821.0K |
| Earning Date | 09-11-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.39 |
| 52 Week High | $2.50 | $1.60 |
Technical Indicators
Market Signals| Indicator | LXEH | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 34.36 |
| Support Level | $1.37 | N/A |
| Resistance Level | $1.72 | $0.71 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 7.13 | 3.70 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is engaged in providing education services, including high school and vocational education services. It offers private basic education at the primary and junior high school levels. The Group has two reportable segments for operations, including high school and vocational education.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.